In the Finnish Invasive Pneumococcal disease ( FinIP ) trial , we reported vaccine effectiveness and absolute rate reduction against laboratory-confirmed invasive pneumococcal disease ( confirmation by culture or antigen or DNA detection irrespective of serotype ) .